Advocacy intelligence hub — real-time data for patient organizations
to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR greater than or equal to 30 mL/min/1.73 m2
Mayo Clinic — PHASE1
Rodrigo Ruano — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
REBETOL
Schering Corporation
Rivfloza
(NEDOSIRAN)Orphan drugNovo Nordisk
12.1 Mechanism of Action Nedosiran is a double-stranded siRNA, conjugated to GalNAc aminosugar residues. After subcutaneous administration, the GalNAc...
REBETOL
(ribavirin)Orphan drugstandardSchering Corporation
Nucleoside Analog Antiviral [EPC]
Mechanism of Action In cell cultures the inhibitory activity of ribavirin for respiratory syncytial virus (RSV) is selective. The mechanism of action ...
Mauro Schenone, MD, M.D
Mayo Clinic
📍 ROCHESTER, MN
Meredith Atkinson, M.D
Johns Hopkins University
📍 BALTIMORE, MD
Michael Belfort, MD PHD, MD
Baylor College of Medicine
📍 HOUSTON, TX
Rodrigo Ruano, MD, PhD., MD
University of Miami
📍 MIAMI, FL
Kunj R Sheth, MD
Division of Pediatric Urology at Stanford University School of Medicine
📍 FORT WORTH, TX
A A Nassr, MBBCh, MSc, MD
Baylor College of Medicine and Texas Children's Fetal Center
📍 HOUSTON, TX
View all Fetal lower urinary tract obstruction specialists →